View Item 

Show simple item record

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

dc.contributor.authorLonial, Sagaren_US
dc.contributor.authorRichardson, Paul G.en_US
dc.contributor.authorSan Miguel, Jesúsen_US
dc.contributor.authorSonneveld, Pieteren_US
dc.contributor.authorSchuster, Michael W.en_US
dc.contributor.authorBladé, Joanen_US
dc.contributor.authorCavenagh, Jamieen_US
dc.contributor.authorRajkumar, S. Vincenten_US
dc.contributor.authorJakubowiak, Andrzej J.en_US
dc.contributor.authorEsseltine, Dixie-Leeen_US
dc.contributor.authorAnderson, Kenneth C.en_US
dc.contributor.authorHarousseau, Jean-Lucen_US
dc.date.accessioned2010-06-01T19:50:32Z
dc.date.available2010-06-01T19:50:32Z
dc.date.issued2008-10en_US
dc.identifier.citationLonial, Sagar; Richardson, Paul G; San Miguel, JesÚs; Sonneveld, Pieter; Schuster, Michael W; BladÉ, Joan; Cavenagh, Jamie; Rajkumar, S. Vincent; Jakubowiak, Andrzej J; Esseltine, Dixie-Lee; Anderson, Kenneth C; Harousseau, Jean-Luc (2008). "Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma." British Journal of Haematology 143(2): 222-229. <http://hdl.handle.net/2027.42/72974>en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72974
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18713253&dopt=citationen_US
dc.format.extent120135 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2008 Blackwell Publishing Ltden_US
dc.subject.otherBortezomiben_US
dc.subject.otherHaematological Toxicityen_US
dc.subject.otherMultiple Myelomaen_US
dc.subject.otherThromboembolic Eventen_US
dc.titleCharacterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherEmory University, Atlanta, GAen_US
dc.contributor.affiliationotherDana-Farber Cancer Institute, Boston, MA, USAen_US
dc.contributor.affiliationotherHospital Universitario Salamanca, CIC, IBMCC (USAL-CSIC), Spainen_US
dc.contributor.affiliationotherUniversity Hospital Rotterdam, Rotterdam, The Netherlandsen_US
dc.contributor.affiliationotherNY-Presbyterian Hospital, New York, NY, USAen_US
dc.contributor.affiliationotherHaematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spainen_US
dc.contributor.affiliationotherSt Bartholomew’s Hospital, London, UKen_US
dc.contributor.affiliationotherMayo Clinic, Rochester, MNen_US
dc.contributor.affiliationotherMillennium Pharmaceuticals Inc., Cambridge, MA, USAen_US
dc.contributor.affiliationotherHÔpital Hotel-Dieu, Nantes, Franceen_US
dc.identifier.pmid18713253en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72974/1/j.1365-2141.2008.07321.x.pdf
dc.identifier.doi10.1111/j.1365-2141.2008.07321.xen_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceAdams, J. & Kauffman, M. ( 2004 ) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investigation, 22, 304 – 311.en_US
dc.identifier.citedreferenceAuwerda, J.J., Sonneveld, P., de Maat, M.P. & Leebeek, F.W. ( 2007 ) Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica, 92, 279 – 280.en_US
dc.identifier.citedreferenceAvcu, F., Ural, A.U., Cetin, T. & Nevruz, O. ( 2008 ) Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thrombosis Research, 121, 567 – 571.en_US
dc.identifier.citedreferenceBaldwin, A.S. ( 2001 ) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. Journal of Clinical Investigation, 107, 241 – 246.en_US
dc.identifier.citedreferenceBarlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. ( 2006 ) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021 – 1030.en_US
dc.identifier.citedreferenceBennett, C.L., Angelotta, C., Yarnold, P.R., Evens, A.M., Zonder, J.A., Raisch, D.W. & Richardson, P. ( 2006 ) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA, 296, 2558 – 2560.en_US
dc.identifier.citedreferenceCavo, M., Patriarca, F., Tacchetti, P., Galli, M., Perrone, G., Petrucci, M.T., Briolli, A., Bringhen, S., Pantani, L., Tosi, P., Crippa, C., Zamagni, E., Di Raimondo, F., Narni, F., Cellini, C., Ceccolini, M., Pescosta, N., Goldaniga, M.C., Montefusco, V., Callea, V., De Stefano, V., Caravita, T., Boccadoro, M. & Baccarani, M. ( 2007 ) Bortezomib (Velcade®)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood, 110, 30a.en_US
dc.identifier.citedreferenceChanan-Khan, A.A., Padmanabhan, S., Miller, K.C., Musiel, L., Yu, J., Bernstein, Z.P., Manochakian, R. & Czuczman, M.S. ( 2006 ) Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma. Blood, 108, 1010a.en_US
dc.identifier.citedreferenceChanan-Khan, A.A., Miller, K.C., DePaolo, D., Padmanabhan, S., Whitworth, A., Ailawadhi, S., Lee, K. & Czuczman, M.S. ( 2007 ) Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT) for the treatment of previously untreated multiple myeloma. Blood, 110, Abstract 3614, 1057a – 1058a.en_US
dc.identifier.citedreferenceCiolli, S., Leoni, F., Casini, C., Breschi, C. & Bosi, A. ( 2007 ) Liposomal doxorubicin increases the anti-tumor efficacy of low dose bortezomib, thalidomide and dexamethasone therapy in advanced multiple myeloma. Haematologica, 92, 94 – 95.en_US
dc.identifier.citedreferenceDimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San, M.J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. ( 2007 ) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123 – 2132.en_US
dc.identifier.citedreferenceElice, F., Fink, L., Tricot, G., Barlogie, B. & Zangari, M. ( 2006 ) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. British Journal Haematology, 134, 399 – 405.en_US
dc.identifier.citedreferenceHamaguchi, E., Takamura, T., Shimizu, A. & Nagai, Y. ( 2003 ) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics, 307, 987 – 994.en_US
dc.identifier.citedreferenceHarousseau, J.-L., Attal, M., Leleu, X., Troncy, J., Pegourie, B., Stoppa, A.-M., Hulin, C., Benboubker, L., Fuzibet, J.-G., Renaud, M., Moreau, P. & Avet-Loiseau, H. ( 2006 ) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 91, 1498 – 1505.en_US
dc.identifier.citedreferenceHarousseau, J.L., Mathiot, C., Attal, M., Marit, G., Caillot, D., Mohty, M., Hulin, C., Facon, T., Webb, I. & Moreau, P. ( 2007 ) VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood, 110, 139a.en_US
dc.identifier.citedreferenceHussein, M.A. ( 2006 ) Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Journal of Thrombosis and Haemostasis, 95, 924 – 930.en_US
dc.identifier.citedreferenceHussein, M.A., Baz, R., Srkalovic, G., Agrawal, N., Suppiah, R., Hsi, E., Andresen, S., Karam, M.A., Reed, J., Faiman, B., Kelly, M. & Walker, E. ( 2006 ) Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clinic Proceedings, 81, 889 – 895.en_US
dc.identifier.citedreferenceJagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D.L., Schenkein, D.P. & Anderson, K.C. ( 2004 ) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal Haematology, 127, 165 – 172.en_US
dc.identifier.citedreferenceJagannath, S., Durie, B.G.M., Wolf, J.L., Camacho, E.S., Irwin, D., Lutzky, J., McKinley, M., Gabayan, A.E., Mazumder, A., Crowley, J. & Vescio, R. ( 2006 ) Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood, 108, 238a – 239a.en_US
dc.identifier.citedreferenceJagannath, S., Bensinger, B., Vescio, R., Camacho, E., Wolf, J., Irwin, D., Capo, G., McKinley, M., Vesole, D.H., Mazumder, A., Crowley, J., Esseltine, D. & Durie, B. ( 2007 ) A phase II study of bortezomib (Velcade®), cylophosphamide (Cytoxan®), thalidomide (Thalomid®) and dexamethasone as first-line therapy for multiple myeloma. Blood, 110, 63a.en_US
dc.identifier.citedreferenceKaufman, R.M. & Anderson, K.C. ( 2003 ) Hematologic complications and blood bank support. In: Cancer Medicine 6 ( ed. by D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast Jr., T.S. Gansler, J.F. Holland & E. Frei III ), pp. 2489 – 2506. BC Decker, Hamilton, ON, Canada.en_US
dc.identifier.citedreferenceKnight, R., DeLap, R.J. & Zeldis, J.B. ( 2006 ) Lenalidomide and venous thrombosis in multiple myeloma. New England Journal of Medicine, 354, 2079 – 2080.en_US
dc.identifier.citedreferenceLiu, F., Morris, S., Epps, J. & Carroll, R. ( 2002 ) Demonstration of an activation regulated NF-kappaB/I-kappaBalpha complex in human platelets. Thrombosis Research, 106, 199 – 203.en_US
dc.identifier.citedreferenceLonial, S., Waller, E.K., Richardson, P.G., Jagannath, S., Orlowski, R.Z., Giver, C.R., Jaye, D.L., Francis, D., Giusti, S., Torre, C., Barlogie, B., Berenson, J.R., Singhal, S., Schenkein, D.P., Esseltine, D.L., Anderson, J., Xiao, H., Heffner, L.T. & Anderson, K.C. ( 2005 ) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 106, 3777 – 3784.en_US
dc.identifier.citedreferenceNiesvizky, R., Spencer, A., Wang, M., Weber, D., Chen, C., Dimopoulos, M.A., Yu, Z., Delap, R., Zeldis, J. & Knight, R.D. ( 2006 ) Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. Journal of Clinical Oncology, 24, 423s.en_US
dc.identifier.citedreferenceNiesvizky, R., Jayabalan, D.S., Christos, P.J., Furst, J.R., Naib, T., Ely, S., Jalbrzikowski, J., Pearse, R.N., Zafar, F., Pekle, K., Larow, A., Lent, R., Mark, T., Cho, H.J., Shore, T., Tepler, J., Harpel, J., Schuster, M.W., Mathew, S., Leonard, J.P., Mazumdar, M., Chen-Kiang, S. & Coleman, M. ( 2008 ) BiRD (Biaxin(R)[clarithromycin]/Revlimid(R)[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood, 111, 1101 – 1109.en_US
dc.identifier.citedreferenceOsman, K., Comenzo, R. & Rajkumar, S.V. ( 2001 ) Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]. New England Journal of Medicine, 344, 1951 – 1952.en_US
dc.identifier.citedreferencePal, R., Kennedy, R., Mansour, L.R., Stirling, D., Mapara, M.Y., Roodman, G.D. & Lentzsch, S. ( 2007 ) Cathepsin G, a potent platelet aggregation activator, is upregulated in multiple myeloma patients during treatment with lenalidomide (Revlimid). Blood, 110, Abstract 2504, 738a.en_US
dc.identifier.citedreferencePalumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. & Boccadoro, M. ( 2006 ) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825 – 831.en_US
dc.identifier.citedreferencePalumbo, A., Ambrosini, M.T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F. & Boccadoro, M. ( 2007a ) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 109, 2767 – 2772.en_US
dc.identifier.citedreferencePalumbo, A., Cavo, M., Bringhen, S., Perrone, G., Magarotto, V., Patriarca, F., Petrucci, M.T., Galli, M., Di Raimondo, F., Rossi, D., Marasca, R., Offidani, M., Goldaniga, M., Corradini, P., Crippa, C., Catalano, L., Callea, V., Gozzini, A., Tosi, P. & Boccadaro, M. ( 2007b ) A prospective, randomized, phase III study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens. Blood, 110, Abstract 310, 98a.en_US
dc.identifier.citedreferenceParry, G.C. & Mackman, N. ( 1995 ) Transcriptional regulation of tissue factor expression in human endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 612 – 621.en_US
dc.identifier.citedreferenceRajkumar, S.V. ( 2005 ) Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic Proceedings, 80, 1549 – 1551.en_US
dc.identifier.citedreferenceRajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. ( 2002 ) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 4319 – 4323.en_US
dc.identifier.citedreferenceRajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R. ( 2006 ) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 – 436.en_US
dc.identifier.citedreferenceRichardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. ( 2003 ) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 – 2617.en_US
dc.identifier.citedreferenceRichardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. ( 2005 ) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 – 2498.en_US
dc.identifier.citedreferenceRichardson, P.G., Jagannath, S., Avigan, D.E., Alsina, M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Ghobrial, I., Doss, D., McKenney, M., Farrell, M.G., Warren, D.L., Lunde, L.E., Gourley, B., Vaccaro, S., Delaney, C., Pountney, S., Mitsiades, C.S., Hideshima, T., Byrne, C., Knight, R., Birner, A., Myers, T., Weller, E. & Anderson, K.C. ( 2006 ) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood, 108, 124a.en_US
dc.identifier.citedreferenceRichardson, P., Jagannath, S., Raje, N., Jakubowiak, A., Lonial, S., Avigan, D., Ghobrial, I., Schlossman, R., Mazumder, A., Munshi, N., Joyce, R., Doss, D., Warren, D., Hayes, S., Giove, L., Kaster, S., Delaney, C., Lauria, M., Mitsiades, C., Hideshima, T., Knight, R., Esseltine, D.-L. & Anderson, K. ( 2007a ) Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study. Blood, 110, Abstract 187, 63a.en_US
dc.identifier.citedreferenceRichardson, P., Jagannath, S., Raje, N., Jakubowiak, A., Lonial, S., Ghobrial, I., Schlossman, R., Mazumder, A., Munshi, N., Colson, K., McKenney, M., Farrell, M., Lunde, L., Giove, L., Kaster, S., Mitsiades, C., Hideshima, T., Knight, R., Esseltine, D.-L. & Anderson, K. ( 2007b ) Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. Blood, 110, Abstract 2714, 797a.en_US
dc.identifier.citedreferenceSohn, R.H., Deming, C.B., Johns, D.C., Champion, H.C., Bian, C., Gardner, K. & Rade, J.J. ( 2005 ) Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood, 105, 3910 – 3917.en_US
dc.identifier.citedreferenceSrkalovic, G., Cameron, M.G., Rybicki, L., Deitcher, S.R., Kattke-Marchant, K. & Hussein, M.A. ( 2004 ) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer, 101, 558 – 566.en_US
dc.identifier.citedreferenceTerpos, E., Anagnostopoulos, A., Heath, D., Kastritis, E., Christoulas, D., Anagnostopoulos, N., Roussou, M., Tsionos, K., Croucher, P. & Dimopoulos, M.A. ( 2006 ) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1-alpha and angiogenic cytokines. Blood, 108, 1010a – 1011a.en_US
dc.identifier.citedreferenceUrbauer, E., Kaufmann, H., Nosslinger, T., Raderer, M. & Drach, J. ( 2002 ) Thromboembolic events during treatment with thalidomide. Blood, 99, 4247 – 4248.en_US
dc.identifier.citedreferenceWang, M., Giralt, S., Delasalle, K., Handy, B. & Alexanian, R. ( 2007 ) Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 12, 235 – 239.en_US
dc.identifier.citedreferenceWeber, D., Rankin, K., Gavino, M., Delasalle, K. & Alexanian, R. ( 2003 ) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology, 21, 16 – 19.en_US
dc.identifier.citedreferenceWeber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. ( 2007 ) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 – 2142.en_US
dc.identifier.citedreferenceZangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., Morris, C., Toor, A., Siegel, E., Fink, L. & Tricot, G. ( 2001 ) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 98, 1614 – 1615.en_US
dc.identifier.citedreferenceZangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L. & Tricot, G. ( 2002 ) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood, 100, 1168 – 1171.en_US
dc.identifier.citedreferenceZangari, M., Saghafifar, F., Mehta, P., Barlogie, B., Fink, L. & Tricot, G. ( 2003 ) The blood coagulation mechanism in multiple myeloma. Seminars in Thrombosis and Hemostasis, 29, 275 – 282.en_US
dc.identifier.citedreferenceZangari, M., Barlogie, B., Burns, M.J., Bolejack, V., Hollmig, K.A., van Rhee, F., Pineda-Roman, M., Elice, F. & Tricot, G.J. ( 2005 ) Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. Blood, 106, 717a.en_US
dc.identifier.citedreferenceZangari, M., Elice, F., Fink, L. & Tricot, G. ( 2007a ) Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy, 7, 307 – 315.en_US
dc.identifier.citedreferenceZangari, M., Guerrero, J., Cavallo, F., Burns, M.J., Prasad, K., Adcock, D., Marlar, R., Tricot, G. & Fink, L. ( 2007b ) Coagulation-related effect of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Blood, 110, Abstract 2733, 803a.en_US
dc.identifier.citedreferenceZhang, L., Zhang, Z.G., Liu, X., Hozeska, A., Stagliano, N., Riordan, W., Lu, M. & Chopp, M. ( 2006 ) Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thrombosis and Haemostasis, 95, 166 – 173.en_US
dc.identifier.citedreferenceZonder, J.A. ( 2006 ) Thrombotic complications of myeloma therapy. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 1, 348 – 355.en_US
dc.identifier.citedreferenceZuckerman, K.S. ( 1998 ) Hematopoietic abnormalities in patients with cancer. Cancer Control, 5, 6 – 11.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2141.2008.07321.x.pdf
Size:
117.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.